This paper explores excessive prices at the intersection between competition law and regulated sectors such as pharma. It was prepared as a background note for the OECD Competition Committee roundtable on “Excessive pricing in pharmaceuticals”, which took place in November 2018.
Excessive Pricing in Pharmaceuticals
Policy paper
OECD Roundtables on Competition Policy Papers
Share
Facebook
Twitter
LinkedIn
Abstract
In the same series
-
Policy paper19 September 2024
Related publications
-
Policy paper19 September 2024